Monaco Asset Management SAM Has $1.43 Million Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Monaco Asset Management SAM increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 26.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the company’s stock after buying an additional 41,849 shares during the period. Monaco Asset Management SAM owned 0.08% of Maravai LifeSciences worth $1,432,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in shares of Maravai LifeSciences by 62,802.8% in the fourth quarter. Russell Investments Group Ltd. now owns 112,596 shares of the company’s stock worth $738,000 after acquiring an additional 112,417 shares during the last quarter. Victory Capital Management Inc. raised its position in Maravai LifeSciences by 237.4% in the 4th quarter. Victory Capital Management Inc. now owns 110,468 shares of the company’s stock worth $724,000 after purchasing an additional 77,727 shares during the last quarter. M&T Bank Corp lifted its holdings in Maravai LifeSciences by 17.3% during the 4th quarter. M&T Bank Corp now owns 20,107 shares of the company’s stock worth $131,000 after buying an additional 2,972 shares in the last quarter. National Bank of Canada FI boosted its position in Maravai LifeSciences by 509,962.5% in the 4th quarter. National Bank of Canada FI now owns 204,025 shares of the company’s stock valued at $1,375,000 after buying an additional 203,985 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in shares of Maravai LifeSciences in the 4th quarter valued at $225,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MRVI. Royal Bank of Canada reaffirmed an “outperform” rating and set a $15.00 price target on shares of Maravai LifeSciences in a research note on Friday, August 16th. The Goldman Sachs Group upped their target price on shares of Maravai LifeSciences from $7.00 to $8.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. UBS Group raised their target price on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Wells Fargo & Company started coverage on shares of Maravai LifeSciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price target for the company. Finally, Morgan Stanley cut shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $11.00 to $10.00 in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and an average price target of $10.78.

Maravai LifeSciences Stock Down 2.0 %

Shares of NASDAQ MRVI opened at $8.87 on Tuesday. Maravai LifeSciences Holdings, Inc. has a 52-week low of $4.52 and a 52-week high of $11.56. The company has a debt-to-equity ratio of 0.71, a quick ratio of 9.28 and a current ratio of 10.00. The stock has a market cap of $2.23 billion, a P/E ratio of -8.96 and a beta of 0.01. The firm has a 50 day moving average price of $8.66 and a 200 day moving average price of $8.51.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $73.40 million during the quarter, compared to analyst estimates of $71.64 million. Maravai LifeSciences had a negative net margin of 47.41% and a negative return on equity of 4.78%. Maravai LifeSciences’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period last year, the firm earned ($0.06) EPS. Analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.17 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.